Tags : PF708

Alvogen Signs an Exclusive Commercialization Agreement with Three Pharma Companies

Vartika Singh October 23, 2019

Shots: Alvogen collaborates with PharmBio, Kamada and Jamp to commercialize PF708 for the treatment of osteoporosis in South Korea, Israel and Canada respectively The focus of the collaboration is to build strong commercial networks in South Korea, Israel and Canada and to gain commercial expertise within the territories PF708 is a biosimilar referencing Eli Lilly’s […]Read More

Pfenex Reports Results of Human Factors Study for its PF708

Vartika Singh October 14, 2019

The follow on study involves assessing of PF708 vs Forteo in 102 patients including 52 with osteoporosis and 50 with caregivers The study demonstrated PF708 had fewer or equal user errors showing 33% and 17 % of critical tasks respectively further concluded that the study data of user interface of the FDA-approved PF708 product is […]Read More

Alvogen and Pfenex’s PF708 (biosimilar, teriparatide) Receives FDA’s Approval for

Vartika Singh October 7, 2019

Shots: The US FDA has granted approval to PF708, a biosimilar of Eli Lilly’s Forteo (teriparatide injection) under the 505(b)(2) regulatory pathway for the treatment of osteoporosis in certain patients at high risk for fracture Pfenex will receive a $2.5M milestone from Alvogen on its approval in the US. The PF708 is the first approved […]Read More

Pfenex and Alvogen Report EMA’s Acceptance of MAA for PF708

Tuba Khan June 1, 2019

Shots: Pfenex and Alvogen announce that EMA has accepted MAA for its PF708, a biosimilar to Eli Lilly’s Forsteo which has generated $289M in EU & $1.6B globally in 2018 for the treatment of osteoporosis is expected to receive marketing authorization in all 28 states of EU, as well as in Iceland, Liechtenstein and Norway, […]Read More

Alvogen Expands Development and Commercialization Collaboration with Pfenex for PF708

Vartika Singh March 1, 2019

Shots: Pfenex to receive $2.5M as upfront and milestones for EU & MENA, milestones for ROW & 60% profit split on sales. Alvogen’s subsidiary Theramex & SAJA to get rights to develop and commercialize in EU, Switzerland & MENA respectively (Ex-Mainland China, Hong Kong, Singapore, Malaysia and Thailand) undisclosed in ROW On 11 Jun,2018 Pfenex […]Read More

ImmunoGen Signs an Agreement with Huadong to Develop & Commercialize Mirvetuximab Soravtansine in Greater China

Takeda Signs ~$1B Pact with Arrowhead for ARO-AAT Targeting Alpha-1 Antitrypsin-Associated Liver Disease

Regeneron’s Inmazeb (atoltivimab, maftivimab, and odesivimab) Receives the US FDA’s Approval as the First Treatment for Ebola

Roche Signs a License Agreement with Dyno to Develop AVV Gene Therapy for ~$1.8B

Henlius Signs a License Agreement with Essex to Co-develop HLX04 (biosimilar, bevacizumab) for Ophthalmic Diseases

Innovent and Lilly’s Halpryza (biosimilar, rituximab) Receive NMPA’s Approval in China

Eli Lilly Pauses Enrollment in ACTIV-3 Clinical Trial Due to Safety Concerns

AstraZeneca Advances its AZD7442 in Two P-III Clinical Studies for COVID-19

AstraZeneca’s Tagrisso (osimertinib) Receives the US FDA’s Priority Review for the Adjuvant Treatment of Patients with Early-Stage EGFR-Mutated Lung Cancer

AbbVie Submits Regulatory Applications to the US FDA and EMA for Rinvoq (upadacitinib) to Treat Atopic Dermatitis

Galapagos & Servier’s GLPG1972/S201086 Fails to Meet its Primary Endpoint in P-II ROCCELLA Study for Knee Osteoarthritis

Sanofi and Translate Bio to Advance MRT5500 into Clinical Study Against COVID-19

Tags : PF708

Alvogen Signs an Exclusive Commercialization Agreement with Three Pharma Companies

Pfenex Reports Results of Human Factors Study for its PF708

Alvogen and Pfenex’s PF708 (biosimilar, teriparatide) Receives FDA’s Approval for

Pfenex and Alvogen Report EMA’s Acceptance of MAA for PF708

Alvogen Expands Development and Commercialization Collaboration with Pfenex for PF708

Latest Posts

ViewPoints Interview: QIAGEN’s Kai te Kaat Shares Insights on QIAprep&amp Viral RNA UM Kit

Bayer and 111 Collaborate to Explore the Vast Blue Ocean of Online Healthcare in China

AstraZeneca’s Tagrisso (osimertinib) Receives the US FDA’s Priority Review for the Adjuvant Treatment of Patients with Early-Stage EGFR-Mutated Lung Cancer

Endo to Acquire BioSpecifics for ~ $540M

Tags : PF708

Latest Posts

Categories

Related Topics